488 related articles for article (PubMed ID: 33189789)
1. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
2. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
3. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
4. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
5. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
6. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
[TBL] [Abstract][Full Text] [Related]
7. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; CichoĊ T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
9. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
[TBL] [Abstract][Full Text] [Related]
10. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
[TBL] [Abstract][Full Text] [Related]
11. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
Xie X; Liu J; Wang X
Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation of STING Agonist cGAMP with Folic Acid-Conjugated Liposomes Significantly Enhances Antitumor Pharmacodynamic Effect.
Lu X; Cheng H; Xu Q; Tan X
Cancer Biother Radiopharm; 2023 Oct; 38(8):543-557. PubMed ID: 33719535
[No Abstract] [Full Text] [Related]
14. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
15. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
[TBL] [Abstract][Full Text] [Related]
16. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.
Nguyen DC; Shae D; Pagendarm HM; Becker KW; Wehbe M; Kilchrist KV; Pastora LE; Palmer CR; Seber P; Christov PP; Duvall CL; Wilson JT
Adv Healthc Mater; 2021 Jan; 10(2):e2001056. PubMed ID: 33225632
[TBL] [Abstract][Full Text] [Related]
18. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
19. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]